Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Thermo Fisher Scientific, Luminex, Eurofins, and More

NEW YORK – Thermo Fisher Scientific and the University of California, Davis West Coast Metabolomics Center announced this week that they have jointly formed the Center of Excellence in Clinical Metabolomics.

The center, which will be based on the UC Davis Sacramento campus, will enable targeted and untargeted metabolic profiling for large-scale population-based cohorts in translational research and precision medicine. It will develop standardized processes for the research community, including end-to-end metabolic profiling workflows; optimized liquid chromatography-mass spectrometry methods and protocols to monitor instrument performance; and training courses for metabolomics staff, scientists and core lab managers.

Thermo Fisher is providing its Orbitrap technology.

Also this week, Thermo Fisher said that its board has authorized a quarterly cash dividend of $.26 per common share, payable on Oct. 15 to shareholders of record as of Sept. 15.

Luminex said this week that it has received approval from the Committee on Foreign Investment in the US for its previously announced merger with DiaSorin. In a document filed with the US Securities and Exchange Commission, Luminex said it anticipates that the deal will close on or about July 14. In April, DiaSorin announced it had signed an agreement to acquire Luminex for approximately $1.8 billion in cash.

Eurofins Transplant Genomics said this week that its TruGraf proprietary gene expression test for subclinical acute rejection in kidney transplant patients has received coverage from Humana. The payor will offer in-network coverage of the blood test for Medicare Advantage, Medicare HMO, Medicare Network PFFS, Medicare POS, and Medicare PPO patients effective Aug. 1. The test detects subclinical acute rejection in patients with stable kidney function before organ injury and chronic acute rejection begins.

Informatics and digital pathology firm Inspirata announced this week that its UK subsidiary Inspirata Europe received ISO 9001 Quality Management System certification, as well as a UK-backed cybersecurity accreditation. Achieving ISO 9001 means Inspirata’s pathology and oncology artificial intelligence solutions are approved for full inclusion on the Medical IT Departmental Software and Hardware Solutions framework operated by the National Health Service Supply Chain.

Inspirata began the process in late 2020 and underwent two audits in spring 2021 to achieve certification.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.